| Literature DB >> 25551070 |
Gun Jik Kim1, Jong Tae Lee1, Young Ok Lee1, Joon Young Cho1, Tak-Hyuk Oh1.
Abstract
BACKGROUND: Most surgeons favor the pledgeted suture technique for heart valve replacements because they believe it decreases the risk of paravalvular leak (PVL). We hypothesized that the use of nonpledgeted rather than pledgeted sutures during mitral valve replacement (MVR) may decrease the incidence of prosthetic valve endocarditis (PVE) and risk of a major PVL.Entities:
Keywords: Mitral valve, replacement; Morbidity; Suture techniques
Year: 2014 PMID: 25551070 PMCID: PMC4279844 DOI: 10.5090/kjtcs.2014.47.6.504
Source DB: PubMed Journal: Korean J Thorac Cardiovasc Surg ISSN: 2233-601X
Fig. 1The number of nonpledgeted sutures gradually increased over this period, albeit with some fluctuations. The simultaneous use of both nonpledgeted and pledgeted sutures remained rare, and pledgeted sutures have been rarely used since 2006.
Preoperative and operative variables for patients undergoing mitral valve replacement, with or without tricuspid valve surgery and Maze operation, comparing nonpledgeted versus pledgeted suture procedures (n=263)
| Variable | Pledgeted (n=88) | Nonpledgeted (n=175) | p-value |
|---|---|---|---|
| Preoperative | |||
| Age (yr) | 48.8±10.8 | 57.5±11.6 | 0.000 |
| Sex (female) | 68 (77.3) | 113 (64.6) | 0.036 |
| Hypertension | 4 (5.8) | 41 (23.4) | 0.001 |
| Major adverse cardiac and cerebrovascular event | 12 (17.4) | 55 (31.4) | 0.027 |
| Diabetes mellitus | 3 (4.3) | 28 (16.0) | 0.014 |
| Atrial fibrillation | 62 (70.5) | 110 (62.9) | 0.222 |
| New York Heart Association class | 0.206 | ||
| I–II | 13 (15.1) | 38 (21.7) | |
| III–IV | 73 (84.9) | 137 (78.3) | |
| Etiology | 0.007 | ||
| Rheumatic | 60 (67.4) | 81 (46.6) | |
| Degenerative | 15 (16.9) | 44 (25.1) | |
| Prosthetic valve failure | 9 (10.1) | 29 (16.7) | |
| Infective endocarditis | 4 (4.5) | 21 (12.0) | |
| Renal failure | 2 (2.9) | 11 (6.3) | |
| Left ventricular ejection fraction severe dysfunction (<30%) | 2 (2.8) | 7 (4.0) | 0.641 |
| Dominance of mitral disease | 0.050 | ||
| Mitral stenosis | 57 (68.7) | 96 (55.8) | |
| Mitral regurgitation | 26 (31.3) | 76 (44.2) | |
| Operative | |||
| Prosthesis type | 0.000 | ||
| Bioprosthesis | 7 (8.0) | 111 (63.4) | |
| Mechanical prosthesis | 81 (92.0) | 64 (36.6) | |
| Valve size (mm) | 0.057 | ||
| 25 | 4 (4.5) | 0 | |
| 27 | 36 (40.9) | 72 (41.1) | |
| 29 | 39 (44.3) | 81 (46.3) | |
| 31 | 7 (8.0) | 20 (11.4) | |
| 33 | 2 (2.3) | 2 (1.1) | |
| Aortic cross-clamp time (min) | 76.0±29.9 | 79.0±25.0 | 0.426 |
| Cardiopulmonary bypass time (min) | 123.0±52.4 | 120.6±43.0 | 0.714 |
Values are presented as mean±standard deviation or number (%).
Postoperative morbidity and mortality for patients undergoing mitral valve replacement, with or without tricuspid valve surgery and Maze operation (n=263)
| Variable | Pledgeted (n=88) | Nonpledgeted (n=175) | p-value |
|---|---|---|---|
| Acute renal failure | 1 (1.4) | 7 (4.0) | 0.314 |
| Reoperation for bleeding | 1 (1.4) | 15 (8.6) | 0.043 |
| Low cardiac output syndrome | 7 (10.1) | 7 (4.0) | 0.063 |
| Arrhythmias | 11 (15.9) | 29 (16.6) | 0.905 |
| Stroke | 9 (13.0) | 10 (5.7) | 0.054 |
| Prosthetic valve endocarditis | 1 (1.1) | 5 (2.9) | 0.368 |
| Major paravalvular leak | 1 (1.1) | 5 (2.9) | 0.378 |
| Reoperation for paravalvular leak | 0 | 3 (1.7) | 0.217 |
| Early mortality | 5 (7.4) | 4 (2.3) | 0.060 |
Values are presented as number (%).